EG 62054
Alternative Names: EG-62054Latest Information Update: 04 Aug 2022
At a glance
- Originator EirGenix
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 01 Aug 2022 Preclinical trials in Unspecified in Taiwan (unspecified route) (EirGenix pipeline, August 2022)